May 31, 2024 10:58 AM EDT
News Briefing

No­var­tis shares up­dat­ed da­ta for BTK in­hibitor; Astel­las re­sub­mits BLA for can­cer drug af­ter CRL

ENDPOINTS

Plus, news about Valar Labs, Pharm­ing Group and Day One Phar­ma­ceu­ti­cals:

No­var­tis out­lines one-year da­ta for BTK in­hibitor: The drug, called remi­bru­ti­nib,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times